Thakur Shikha, Kumar Devendra, Jaiswal Shivani, Goel Kapil Kumar, Rawat Pramod, Srivastava Vivek, Dhiman Sonia, Jadhav Hemant R, Dwivedi Ashish Ranjan
Pharmaceutical Chemistry Laboratory, Department of Pharmacy, Birla Institute of Technology and Sciences Pilani Pilani Campus, Vidya Vihar Pilani - 333031 RJ India
School of Pharmacy, Narsee Monjee Institute of Management Studies (NMIMS) Dist. Dhule Maharashtra India.
RSC Med Chem. 2024 Oct 30. doi: 10.1039/d4md00450g.
Thiophene is a privileged pharmacophore in medicinal chemistry owing to its diversified biological attributes. The thiophene moiety has been ranked 4th in the US FDA drug approval of small drug molecules, with around 7 drug approvals over the last decade. The present review covers USFDA-approved drugs possessing a thiophene ring system. Our analysis reveals that 26 drugs possessing thiophene nuclei have been approved under different pharmacological classes. The review further covers reported thiophene and its substituted analogues with diverse biological activities, including anti-diabetic, anticancer, anti-inflammatory, anticonvulsant, and antioxidant activity. Besides, a section is dedicated to appreciating the implications of structural bioinformatics in drug discovery. Additionally, the manuscript delves into structure-activity relationship studies to explore the chemical groups responsible for eliciting potential therapeutic activities. The review may provide invaluable insights for researchers working with thiophene nuclei in developing novel analogues with greater efficacy and fewer side effects.
由于其多样的生物学特性,噻吩是药物化学中一种重要的药效基团。噻吩部分在美国食品药品监督管理局(US FDA)批准的小分子药物中排名第四,在过去十年中约有7种药物获批。本综述涵盖了US FDA批准的具有噻吩环系统的药物。我们的分析表明,有26种含有噻吩核的药物已在不同的药理学类别下获批。该综述还涵盖了报道的具有多种生物活性的噻吩及其取代类似物,包括抗糖尿病、抗癌、抗炎、抗惊厥和抗氧化活性。此外,有一部分内容专门阐述了结构生物信息学在药物发现中的意义。此外,本文深入探讨了构效关系研究,以探索引发潜在治疗活性的化学基团。该综述可能为研究噻吩核的研究人员开发具有更高疗效和更少副作用的新型类似物提供宝贵的见解。